Clinical Scorecard: GLP-1 Receptor Agonist Use and Obesity-Related Cancer Risk Across Levels of Diabetes Severity

At a Glance

Key Highlights

• At 3 years, GLP-1 RA initiation was associated with lower ORC risk than insulin (RD −1.25% [95% CI, −1.74% to −0.83%]; HR 0.62 [95% CI, 0.49-0.77]) and sulfonylureas (RD −1.14% [95% CI, −1.85% to −0.51%]; HR 0.67 [95% CI, 0.54-0.84]).
• At 5 years, the RD versus insulin was −1.67% (95% CI, −2.36% to −1.11%); HRs were 0.61 versus insulin (95% CI, 0.50-0.75) and 0.75 versus sulfonylureas (95% CI, 0.61-0.92).
• Estimates versus metformin, SGLT2 inhibitors, and DPP4 inhibitors were closer to the null; results versus these comparators were not consistently different.
• Associations were clearest among adults with lower T2D severity; severity comparisons were exploratory.
• The authors state that findings do not justify choosing glucose-lowering therapy to prevent cancer.

Guideline-Based Recommendations

Diagnosis

• The study defined incident ORC as the first ORC diagnosis and excluded participants with a history of ORC.

Management

• The authors state that established metabolic, cardiovascular, and kidney benefits should remain the basis for glucose-lowering treatment decisions.
• The study does not support selecting glucose-lowering therapy for cancer prevention.

Monitoring & Follow-up

• The authors note that longer follow-up across health systems is needed.

Risks

• Interpretation is limited by residual confounding, incomplete overlap despite weighting, possible exposure and outcome misclassification, broad severity categories, and sparse events in some strata.
• Insulin and SGLT2 inhibitor prescribing pathways may reflect differences in disease severity, glycemic exposure, access, surveillance, and prognosis.
• Many GLP-1 RA initiators entered recently, so 5-year estimates depended disproportionately on earlier initiators.

Patient & Prescribing Data

The cohort included adults with T2D and no prior ORC who initiated a GLP-1 RA or metformin, insulin, an SGLT2 inhibitor, a DPP4 inhibitor, or a sulfonylurea after a 365-day washout. Severity was classified hierarchically: high included macrovascular disease or CKD stages 4-5; moderate included microvascular complications or CKD stages 1-3 without high-severity conditions; low indicated none of these conditions.

GLP-1 RA initiation was associated with lower ORC incidence than insulin or sulfonylureas, particularly in lower-severity T2D; results versus other comparators were not consistently different. The observational findings do not establish treatment superiority for cancer outcomes.

Clinical Best Practices

• The authors caution that the reported associations are observational and do not establish that GLP-1 RAs prevent ORC.
• The authors note that baseline T2D severity and treatment-selection differences should be considered when interpreting medication comparisons.
• The authors state that established metabolic, cardiovascular, and kidney benefits should remain the basis for glucose-lowering treatment decisions.

Related Resources & Content